Cholesterol

dipeptidyl peptidase 4 ; Homo sapiens







32 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 31595792 Adipokine gene expression in adipocytes isolated from different fat depots of coronary artery disease patients. 2022 Feb 1
2 33342939 Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. 2022 Jan 1 1
3 33538983 Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery. 2021 Jun 2
4 33737166 Expectations for synergistically favorable effects of the combination therapy with DPP-4 inhibitor and SGLT2 inhibitor on cholesterol synthesis and absorption. 2021 Jun 15 1
5 34333803 Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. 2021 Dec 1
6 34926239 DPP4 Regulates DHCR24-Mediated Cholesterol Biosynthesis to Promote Methotrexate Resistance in Gestational Trophoblastic Neoplastic Cells. 2021 5
7 31990936 Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial. 2020 2
8 32422444 Serum Dipeptidyl peptidase-4 level is related to adiposity in type 1 diabetic adolescents. 2020 Jul - Aug 1
9 30302966 Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus. 2019 Feb 1
10 30674032 Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. 2019 Jun 1
11 30738832 Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways. 2019 Mar 1
12 31733647 Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. 2019 Nov 16 1
13 28403877 A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. 2017 Apr 13 2
14 31089516 Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees. 2017 Sep 1
15 26752504 Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. 2016 Feb 1
16 27006706 Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. 2016 1
17 27693949 Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes. 2016 Nov 1
18 25294850 Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. 2015 Mar 1
19 26048437 Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. 2015 Dec 2
20 26259132 Plasma DPP4 Activities Are Associated With Osteoporosis in Postmenopausal Women With Normal Glucose Tolerance. 2015 Oct 2
21 26474470 Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects. 2015 2
22 26603933 Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes. 2015 Dec 25 1
23 25110536 Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. 2014 Oct 1
24 23379505 Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome. 2013 Feb 4 1
25 23994650 The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. 2013 Nov 1
26 24362783 [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors]. 2013 Dec 2
27 22179204 Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. 2012 Mar 1
28 22215383 DPP-4 inhibitors and lipids: systematic review and meta-analysis. 2012 Jan 7
29 22398368 5-Aza-2'-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis. 2012 Jul 2
30 22785237 Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. 2012 1
31 22923161 Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. 2012 Sep 1
32 11773049 Intestinal dipeptidyl peptidase IV is efficiently sorted to the apical membrane through the concerted action of N- and O-glycans as well as association with lipid microdomains. 2002 Mar 22 3